Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

NCT05012371 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Advanced Clear Cell Renal Cell Carcinoma
Metastatic Clear Cell Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC v8
Stage IV Renal Cell Cancer AJCC v8

Interventions

DRUG: Cabozantinib
DRUG: Everolimus
DRUG: Lenvatinib
OTHER: Questionnaire Administration

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]